• SENSEX 83,021.75
    989.94 (+1.21%)
  • BANKNIFTY 63,063.00
    1,024.35 (+1.65%)
Back

Results - Announcements

Strides Pharma Science Ltd consolidated sales up 12.99% on year in Q3FY2026
30-Oct-2026, 10:34

Strides Pharma Science Ltd share price ticked higher by 0.91% to Rs 1097.4 after the company's net profit dropped 18.96% to Rs 134.12 crore, while revenue from operations increased 12.99% to Rs 1429.73 crore in Q3FY26 over Q2FY26.


The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, gaining 4.44%. It has improved by 5.74% over last one week and crept higher by 0.60% in last one month while the market capitalization of Strides Pharma Science Ltd has marginally improved by 8.42% and 7.25% in the same period respectively.


Profit before tax (PBT) of Strides Pharma Science Ltd stood at Rs 150.44 crore in Q3 FY26, declining 1.75% year-on-year, and tumbling by 24.64% quarter-on-quarter. EBITDA came in at Rs 247 crore, surging by 20.75% YoY and rising 9.76% sequentially.


Total expenses increased by 13.19% to Rs 1236.04 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 564.95 crore, jumping 36.22% YoY, while employee benefits expense was at Rs 238.27 crore, softening 1.94% YoY.


For the TTM ended FY26, revenue from operations inched higher 6.43% to Rs 4858.68 crore, while net profit soared by 40.33% to Rs 574.52 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 75323% to Rs 774.58 crore, and PBT surged 37.33% to Rs 668.69 crore compared to previous TTM.


The company's consolidated net cash flow from operating activities stood at Rs 702.52 crore in FY26, as against Rs 684.37 crore in FY25.


Strides Pharma Science Ltd surged by 29.11% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 12.76% during the same period.